- Home
- NEXM vs DTIL Comparison
NEXM vs DTIL Comparison
Compare NEXM & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEXM | DTIL |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Canada | United States |
| Employees | N/A | 68 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.1M | 136.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NEXM | DTIL |
|---|---|---|
| Price | $2.52 | $5.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 65.7K | ★ 337.4K |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $3.53 |
| 52 Week High | $6.75 | $8.82 |
Technical Indicators
Market Signals| Indicator | NEXM | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 52.35 |
| Support Level | N/A | $4.66 |
| Resistance Level | $4.25 | $7.59 |
| Average True Range (ATR) | 0.18 | 0.58 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 38.17 | 15.67 |
Price Performance
Historical ComparisonAbout NEXM NexMetals Mining Corp.
NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).